Phil Taylor

Recordati gets €10.9bn takeover bid from private equity firm

New biotech Atrium born out of Novartis/Avidity marriage

Has trial result burst BMS' Cobenfy bubble?

FDA clears Ionis drug as first therapy for rare disease FCS

Insulin pump firm Insulet wins $452m in trade secrets clash

FDA’s ODAC doesn’t vote on AstraZeneca’s perioperative Imfinzi regimen in NSCLC but has deep reservations about the design of the phase 3 trial supporting it

Consumer wearables have shown a benefit when used to monitor treatment responses in patients with atrial fibrillation and heart failure.

As healthcare systems try to recover from major outage event, attention turns to potential fraud and resiliency concerns

Ursula von der Leyen highlights biotech and AI as key sectors in speech as she is re-elected as President of the European Commission

Framework governing early-stage clinical trials in the UK is stifling research and needs to be simplified, says BJCP paper

Novo Holdings leads $100m financing for Swiss biotech Asceneuron, which is developing an oral tau therapy for Alzheimer’s disease

Destiny Pharma has joined a growing list of UK biotech companies seeking to delist from the AIM exchange and return to private ownership

Two investment funds have decided to contest Taisho Pharma’s recently announced management buyout plan in court

Flagship Pioneering raises $3.6bn to fund around 25 startups in human health, sustainability and AI, with $1bn set aside for strategic partnerships

GLP-1 agonists like Novo Nordisk’s Ozempic reduce the risk of 10 of 13 cancers associated with obesity in an observational study.

After Labour landslide in UK general election, former shadow health secretary West Streeting sets out his objectives for the NHS.

Private equity firms Bain Capital and Cinven are reported to be considering a bid for Sanofi’s consumer health business

A study of Novo Nordisk’s semaglutide has found a possible link between the diabetes and obesity drug and a rare condition that causes sight loss.

A UK code of practice has been drawn up to make sure that research on human embryo models derived from stem cells is carried out ethically and responsibly.

A Connecticut federal judge has rejected Boehringer Ingelheim’s challenge to Medicare’s drug price negotiation programme